piperidines and Graves-Ophthalmopathy

piperidines has been researched along with Graves-Ophthalmopathy* in 1 studies

Other Studies

1 other study(ies) available for piperidines and Graves-Ophthalmopathy

Article	Year
The Effects of Mitiglinide and Repaglinide on Postprandial Hyperglycemia in Patients Undergoing Methylprednisolone Pulse Therapy. Internal medicine (Tokyo, Japan), 2018, Jan-01, Volume: 57, Issue:1 One adverse effect of methylprednisolone (MP) pulse therapy is an acute dose-dependent increase in the blood glucose level. Five patients with thyroid ophthalmopathy but normal glucose tolerance received MP pulse therapy (3 cycles, 3 days/week) and were assessed by continuous glucose monitoring. Steroid therapy increased the mean sensor glucose level, and all patients developed steroid-induced diabetes. The patients were treated alternately with mitiglinide (30 mg/day) and repaglinide (1.5 mg/day) during the second or third MP pulse therapy. The sensor glucose levels before lunch and dinner were more favorable during treatment with repaglinide than during treatment with mitiglinide. Repaglinide may be more clinically appropriate than mitiglinide. Topics: Aged; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Female; Graves Ophthalmopathy; Humans; Hyperglycemia; Hypoglycemic Agents; Isoindoles; Male; Methylprednisolone; Middle Aged; Piperidines; Treatment Outcome	2018

Article

Year

The Effects of Mitiglinide and Repaglinide on Postprandial Hyperglycemia in Patients Undergoing Methylprednisolone Pulse Therapy.

Internal medicine (Tokyo, Japan), 2018, Jan-01, Volume: 57, Issue:1

One adverse effect of methylprednisolone (MP) pulse therapy is an acute dose-dependent increase in the blood glucose level. Five patients with thyroid ophthalmopathy but normal glucose tolerance received MP pulse therapy (3 cycles, 3 days/week) and were assessed by continuous glucose monitoring. Steroid therapy increased the mean sensor glucose level, and all patients developed steroid-induced diabetes. The patients were treated alternately with mitiglinide (30 mg/day) and repaglinide (1.5 mg/day) during the second or third MP pulse therapy. The sensor glucose levels before lunch and dinner were more favorable during treatment with repaglinide than during treatment with mitiglinide. Repaglinide may be more clinically appropriate than mitiglinide.

Topics: Aged; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Female; Graves Ophthalmopathy; Humans; Hyperglycemia; Hypoglycemic Agents; Isoindoles; Male; Methylprednisolone; Middle Aged; Piperidines; Treatment Outcome

2018